NewcelX Ltd. (NCEL) Form 6-K — Nov 9, 2026
NewcelX priced a $1.55 million private placement at $3.29 per share, a 20% premium to its November 6, 2026 closing price, selling 471,125 shares plus warrants for 353,344 shares at $3.75. The round was led by international healthcare investors alongside The Crushing T1 Foundation and is expected to close around November 23, 2026. Proceeds will fund the FDA-required IND-enabling toxicology study for NCEL-101, the company's stem cell therapy for type 1 diabetes being developed with Eledon Pharmaceuticals, plus manufacturing capabilities and work toward a planned Phase 1/2a trial in 2027.
Key figures
- Gross Proceeds
- 1550000
- Offering Price
- 3.29
- Shares Offered
- 471125
- Equity line
- $25 million previously announced
- Warrant shares
- 353344
- Premium to market
- 20%
- Warrant exercise price
- 3.75
- Warrant exercise premium
- 137% of last closing price
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.